Payment overview · 2025
General Payments
$146.31
6 reported records · 4 companies
Healthcare provider profile · identity verified
Douglas B Shellhorn, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · SALISBURY, NC · NPI 1972589026
Verified facts
What the public records show
CMS Open Payments records show Douglas B Shellhorn, M.D. received $146.31 in general payments during 2025 across 6 reported records.
Dexcom, Inc. accounted for 41.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $60.30 | 41.2% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $32.27 | 22.1% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $29.45 | 20.1% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $24.29 | 16.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $146.31 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $60.30 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $32.27 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $29.45 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $24.29 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $17.19 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 522 | 142 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 456 | 121 |
| Levothyroxine Sodium | Levothyroxine Sodium | 418 | 100 |
| Atorvastatin Calcium | Atorvastatin Calcium | 337 | 90 |
| Lisinopril | Lisinopril | 303 | 76 |
| Losartan Potassium | Losartan Potassium | 254 | 77 |
| Omeprazole | Omeprazole | 249 | 69 |
| Pantoprazole Sodium | Pantoprazole Sodium | 234 | 65 |
| Gabapentin | Gabapentin | 218 | 53 |
| Carvedilol | Carvedilol | 182 | 49 |
| Hydrochlorothiazide | Hydrochlorothiazide | 182 | 51 |
| Sertraline Hcl | Sertraline Hcl | 182 | 50 |
| Metoprolol Succinate | Metoprolol Succinate | 177 | 52 |
| Metformin Hcl | Metformin Hcl | 166 | 46 |
| Eliquis | Apixaban | 159 | 29 |
| Mounjaro | Tirzepatide | 140 | 22 |
| Furosemide | Furosemide | 138 | 50 |
| Tamsulosin Hcl | Tamsulosin Hcl | 134 | 38 |
| Ozempic | Semaglutide | 120 | 23 |
| Simvastatin | Simvastatin | 108 | 30 |
| Ezetimibe | Ezetimibe | 100 | 36 |
| Prednisone | Prednisone | 94 | 61 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 86 | 62 |
| Donepezil Hcl | Donepezil Hcl | 80 | 22 |
| Clopidogrel | Clopidogrel Bisulfate | 79 | 24 |
| Jardiance | Empagliflozin | 79 | 18 |
| Metformin Hcl Er | Metformin Hcl | 78 | 20 |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 77 | 77 |
| Pravastatin Sodium | Pravastatin Sodium | 77 | 21 |
| Metoprolol Tartrate | Metoprolol Tartrate | 76 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 75 | 18 |
| Montelukast Sodium | Montelukast Sodium | 75 | 23 |
| Alprazolam | Alprazolam | 72 | 19 |
| Meloxicam | Meloxicam | 69 | 18 |
| Tramadol Hcl | Tramadol Hcl | 69 | 26 |
| Trazodone Hcl | Trazodone Hcl | 66 | 23 |
| Lorazepam | Lorazepam | 60 | 27 |
| Citalopram Hbr | Citalopram Hydrobromide | 59 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 59 | 16 |
| Allopurinol | Allopurinol | 57 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 57 | 12 |
| Xarelto | Rivaroxaban | 56 | 12 |
| Potassium Chloride | Potassium Chloride | 51 | 18 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 50 | 45 |
| Zolpidem Tartrate | Zolpidem Tartrate | 50 | 23 |
| Fluticasone Propionate | Fluticasone Propionate | 48 | 19 |
| Glipizide Er | Glipizide | 48 | 15 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 46 | 22 |
| Doxazosin Mesylate | Doxazosin Mesylate | 46 | 13 |
| Synthroid | Levothyroxine Sodium | 46 | 11 |
| Spironolactone | Spironolactone | 45 | suppressed |
| Januvia | Sitagliptin Phosphate | 44 | 14 |
| Warfarin Sodium | Warfarin Sodium | 44 | 13 |
| Atenolol | Atenolol | 42 | suppressed |
| Repatha Sureclick | Evolocumab | 42 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 41 | 24 |
| Paroxetine Hcl | Paroxetine Hcl | 39 | suppressed |
| Entresto | Sacubitril/Valsartan | 38 | suppressed |
| Famotidine | Famotidine | 38 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 37 | suppressed |
| Ketoconazole | Ketoconazole | 37 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 37 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 36 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 36 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 35 | suppressed |
| Celecoxib | Celecoxib | 34 | suppressed |
| Fluconazole | Fluconazole | 34 | 23 |
| Myrbetriq | Mirabegron | 34 | suppressed |
| Finasteride | Finasteride | 33 | suppressed |
| Memantine Hcl | Memantine Hcl | 33 | suppressed |
| Baclofen | Baclofen | 32 | suppressed |
| Fenofibrate | Fenofibrate | 32 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 31 | suppressed |
| Linzess | Linaclotide | 31 | suppressed |
| Clonazepam | Clonazepam | 30 | 11 |
| Levetiracetam | Levetiracetam | 30 | suppressed |
| Tradjenta | Linagliptin | 30 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 30 | suppressed |
| Ampicillin Trihydrate | Ampicillin Trihydrate | 29 | 24 |
| Fluoxetine Hcl | Fluoxetine Hcl | 29 | suppressed |
| Chlorthalidone | Chlorthalidone | 27 | 11 |
| Estradiol | Estradiol | 27 | 13 |
| Nystatin | Nystatin | 27 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 27 | suppressed |
| Ramipril | Ramipril | 27 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 27 | 26 |
| Valacyclovir | Valacyclovir Hcl | 27 | 13 |
| Glimepiride | Glimepiride | 26 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 25 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 25 | suppressed |
| Nitroglycerin | Nitroglycerin | 24 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 24 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 23 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 23 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 22 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 22 | 16 |
| Ondansetron Hcl | Ondansetron Hcl | 22 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 22 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 22 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 21 | suppressed |
| Trulicity | Dulaglutide | 21 | suppressed |
| Verapamil Er | Verapamil Hcl | 21 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 20 | suppressed |
| Pregabalin | Pregabalin | 20 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 19 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 19 | suppressed |
| Cephalexin | Cephalexin | 18 | 14 |
| Diltiazem Hcl | Diltiazem Hcl | 18 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 18 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 17 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 17 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 17 | 14 |
| Ipratropium Bromide | Ipratropium Bromide | 17 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 16 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 16 | suppressed |
| Azithromycin | Azithromycin | 15 | 15 |
| Metoclopramide Hcl | Metoclopramide Hcl | 15 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 15 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Valsartan | Valsartan | 15 | suppressed |
| Gemfibrozil | Gemfibrozil | 14 | suppressed |
| Glipizide | Glipizide | 14 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 14 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 14 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | 12 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 12 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Repatha Syringe | Evolocumab | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $146.31 · 6 records | Dexcom, Inc. | Dexcom G6 Transmitter, EVENITY, FREESTYLE LIBRE 3, GEMTESA, PROLIA | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error